How AI is Changing Drug Labeling and Risk Communication

By Vanessa Muller, PharmD

When a Label Change Reaches the Pharmacy Counter 

In recent years, patients taking commonly prescribed medications, including some high-profile  GLP-1 receptor agonists, have occasionally encountered new warnings added to package inserts and labeling. These updates rarely arrive with dramatic announcements. Instead, pharmacists notice revised counseling language, clinicians see updated alerts in electronic health-record systems, and health plans quietly adjust coverage criteria or monitoring requirements. 

For patients, this change may appear minor, but behind the scenes it often reflects months of pattern identification across adverse-event reports, clinical data, scientific literature, and regulatory review. For patients and clinicians seeking transparency, the FDA’s Drug Safety-related Labeling Changes (SrLC) database provides a public record of recent safety-related updates to prescription drug labeling. Building on earlier work explaining how AI helps regulators detect emerging drug safety issues, the focus here is on what happens next, how safety signals move through regulatory review, becoming labeling changes, and reach clinicians, pharmacies, and health plans.

Where Safety Signals Start

Post-market drug safety has long relied on multiple information streams, including spontaneous adverse-event reports submitted to the FDA Adverse Event Reporting System (FAERS), case reports from clinicians, published medical literature, manufacturer safety updates, and international regulatory alerts coordinated through global drug safety monitoring networks. 

These sources remain foundational, but the volume and complexity of safety data have increased substantially. Regulators now process more than two million adverse-event reports annually through FAERS, alongside expanding use of real-world evidence from electronic health records, claims databases, and observational studies.  

What AI Actually Does in Labeling 

AI’s role in drug labeling is often misunderstood. In regulatory practice, AI tools support information management and prioritization; they do not determine causality or author final label language. 

In real-world safety and labeling workflows, AI may assist with natural language processing to extract themes from narrative adverse-event reports; pattern-recognition methods to cluster similar cases across time and settings; automated screening to surface emerging safety findings; label-comparison tools to identify inconsistencies or emerging adverse reactions across products in the same therapeutic class; and preparation of early internal summaries to support expert review. 

These types of tools are already being piloted and used in drug safety monitoring environments to support earlier detection of potential labeling issues. They function as screening and comparison aids, not as decision-makers. 

Regulatory professionals, including physicians, pharmacists, epidemiologists, and statisticians, assess biological plausibility, confounding factors, and overall benefit–risk balance. Decisions about whether to revise labeling, where warnings should appear, and how risks should be communicated remain human responsibilities.

Guardrails and Rules 

Across regulatory systems, AI use in drug safety monitoring is governed by explicit guardrails. 

In the United States, recent draft FDA guidance addressing the use of AI to support regulatory decision-making for drugs and biologics describes a risk-based credibility framework. This framework emphasizes data quality, bias assessment, validation, transparency, and documentation of a model’s context of use, particularly when AI outputs may inform safety or labeling decisions.

Similarly, the European Medicines Agency’s reflection paper on AI in the medicinal product lifecycle stresses a human-centric approach, with clear legal accountability and oversight across development, safety monitoring, and post-market activities. Health Canada and the World Health Organization have articulated comparable principles. 

Together, these frameworks reflect a shared regulatory direction: AI may assist reviewers, but regulatory judgment, accountability, and final decision-making must remain with trained experts.

Why Limits Matter 

These guardrails exist for a reason. While AI can improve efficiency, it also introduces important limitations.

Safety signals are only as representative as the data submitted, and under-reporting or population gaps can skew results. Algorithms may flag statistical associations that lack clinical relevance, while rare but serious events may remain difficult to detect when reporting is sparse or widely different from one case to the next. 

For this reason, regulators emphasize ongoing validation, performance monitoring, and a human-in-the-loop approach. AI can help identify where questions exist, but trained experts remain the final filter between algorithmic output and regulatory action. 

Reaching the Front Lines 

A label change is not the end of the safety process. Once approved, updated information must move through multiple systems before it reaches patients, including electronic health-record alerts and clinical decision-support tools, pharmacy dispensing software, standing orders and clinical protocols, and health-plan coverage policies and utilization rules.

How well this last mile functions often determines whether safety updates translate into meaningful changes in care.

Risk communication increasingly extends beyond labeling alone. Safety updates may prompt targeted clinician alerts, pharmacy system messaging, direct-to-patient outreach through portals, and follow-up communication when questions or confusion emerge.

For safety-labeling teams, regulatory groups, and payer-facing stakeholders, this means messaging must be aligned across functions. When regulatory language, clinical guidance, and coverage policy diverge, frontline clinicians and patients are left to reconcile inconsistencies on their own.

From Signal to Real-World Communication

In practice, the path from an early safety concern to a labeling update and real-world action follows a predictable sequence. Safety signals are first detected in adverse-event reports or real-world data, then triaged and prioritized using AI-enabled screening tools. Expert reviewers evaluate the evidence to assess causality and clinical context, after which labeling changes are approved through established regulatory processes. 

For example, with widely used GLP-1 receptor agonists, emerging post-market safety data have prompted periodic updates to warnings, precautions, and patient counseling language over time. Once approved, these changes are communicated through updated labeling, electronic health-record alerts, pharmacy systems, and payer policies so that new safety information is reflected in daily practice. 

What This Means in Practice

For patients, the goal is to stay informed and speak up when something feels off. Patients can support medication safety by reporting unexpected side effects through FDA MedWatch, reading messages from pharmacies and healthcare providers, and asking questions when medication guidance changes.

For clinicians and pharmacists, the focus is translation, turning updated safety information into practical care. This includes monitoring label changes and safety communications, aligning counseling and protocols with current warnings, and submitting adverse-event reports to support earlier detection of potential risks.

For health plans and policymakers, alignment is critical. Coverage policies and utilization rules should reflect updated safety information, messaging should be coordinated across systems, and pharmacies should be recognized as essential partners in delivering timely and consistent risk communication.

Conclusion

AI is reshaping how drug-safety information is managed, but not how regulatory decisions are made. By improving signal detection and prioritization, AI enables experts to act earlier and communicate risks more clearly. Its value depends on strong guardrails, human accountability, and coordination across regulatory, clinical, and payer environments.

When safety signals move efficiently from data to decisions and from labeling to real-world practice, patients are better protected, and trust in the medication-use system is strengthened.

Disclosure

The author is a federal pharmacist writing in a personal capacity. The views expressed are her own and do not represent the U.S. Navy or Department of Defense.

References

U.S. Food and Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS): Questions and Answers. Updated 2024–2025. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers.

U.S. Food and Drug Administration (FDA). Drug Safety Communications. 2024–2025. https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications.

U.S. Food and Drug Administration (FDA). Artificial Intelligence and Machine Learning in Regulatory Review. 2025. https://www.fda.gov/science-research/science-and-research-special-topics/artificial-intelligence-and-machine-learning.

FDA Sentinel Initiative. Use of Real-World Evidence and Advanced Analytics in Postmarket Drug Safety. 2024. https://www.sentinelinitiative.org/.

European Medicines Agency (EMA). Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. 2024. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-medicinal-product-lifecycle_en.pdf.

Health Canada. Emerging Technologies in Pharmacovigilance and Regulatory Oversight. 2024. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products.html.

World Health Organization (WHO). Artificial Intelligence in Pharmacovigilance: Opportunities and Challenges. 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-2023.1.

Vallano A, et al. Artificial intelligence in pharmacovigilance: current status and future perspectives. Drug Safety. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328742/.

Assessed and Endorsed by the MedReport Medical Review Board